Phase I study of TAS-102 and irinotecan combination therapy in Japanese patients with advanced colorectal cancer

Background TAS-102 is a nucleoside antitumor agent consisting of trifluridine (FTD) and tipiracil hydrochloride (TPI). We investigated the recommended dose (RD) of TAS-102 plus irinotecan for metastatic colorectal cancer refractory to 5-fluorouracil (5-FU) and oxaliplatin. Methods This study was use...

Descripción completa

Detalles Bibliográficos
Autores principales: Doi, Toshihiko, Yoshino, Takayuki, Fuse, Nozomu, Boku, Narikazu, Yamazaki, Kentaro, Koizumi, Wasaburo, Shimada, Ken, Takinishi, Yasutaka, Ohtsu, Atsushi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2015
Materias:
Phase I Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4768213/
https://www.ncbi.nlm.nih.gov/pubmed/26163340
http://dx.doi.org/10.1007/s10637-015-0271-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4768213/
https://www.ncbi.nlm.nih.gov/pubmed/26163340
http://dx.doi.org/10.1007/s10637-015-0271-1

Ejemplares similares